NVCT Insider Trading

Insider Ownership Percentage: 38.85%
Insider Buying (Last 12 Months): $3,081,356.09
Insider Selling (Last 12 Months): $0.00

Nuvectis Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Nuvectis Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvectis Pharma Share Price & Price History

Current Price: $7.10
Price Change: Price Increase of +0.28 (4.11%)
As of 04/22/2024 01:00 AM ET

This chart shows the closing price history over time for NVCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Nuvectis Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2024Ron BentsurCEOBuy5,000$10.29$51,450.003,242,484View SEC Filing Icon  
10/9/2023Ron BentsurCEOBuy830$11.19$9,287.703,236,844View SEC Filing Icon  
10/6/2023Ron BentsurCEOBuy250$11.27$2,817.503,236,014View SEC Filing Icon  
10/4/2023Ron BentsurCEOBuy1,820$10.95$19,929.003,234,364View SEC Filing Icon  
8/15/2023Ron BentsurCEOBuy235$14.34$3,369.903,232,429View SEC Filing Icon  
8/11/2023Ron BentsurCEOBuy180$14.66$2,638.803,232,194View SEC Filing Icon  
8/8/2023Ron BentsurCEOBuy120$14.83$1,779.603,232,014View SEC Filing Icon  
7/31/2023Marlio Charles MosseriMajor ShareholderBuy860$13.88$11,936.802,595,000View SEC Filing Icon  
7/28/2023Marlio Charles MosseriMajor ShareholderBuy2,584$13.91$35,943.442,594,140View SEC Filing Icon  
7/26/2023Marlio Charles MosseriMajor ShareholderBuy10,000$13.97$139,700.002,590,000View SEC Filing Icon  
7/21/2023Ron BentsurCEOBuy225$14.85$3,341.253,231,894View SEC Filing Icon  
7/20/2023Marlio Charles MosseriMajor ShareholderBuy5,394$14.40$77,673.602,577,156View SEC Filing Icon  
7/19/2023Ron BentsurCEOBuy200$14.33$2,866.003,231,559View SEC Filing Icon  
7/18/2023Marlio Charles MosseriMajor ShareholderBuy9,149$14.84$135,771.162,563,762View SEC Filing Icon  
7/14/2023Ron BentsurCEOBuy150$15.03$2,254.503,231,359View SEC Filing Icon  
7/11/2023Marlio Charles MosseriMajor ShareholderBuy10,000$15.36$153,600.002,551,328View SEC Filing Icon  
7/7/2023Marlio Charles MosseriMajor ShareholderBuy8,948$15.19$135,920.122,541,328View SEC Filing Icon  
7/6/2023Ron BentsurCEOBuy320$14.88$4,761.603,231,099View SEC Filing Icon  
7/5/2023Marlio Charles MosseriMajor ShareholderBuy1,176$15.52$18,251.522,529,201View SEC Filing Icon  
6/26/2023Marlio Charles MosseriMajor ShareholderBuy16,760$16.46$275,869.602,528,025View SEC Filing Icon  
6/26/2023Ron BentsurCEOBuy750$16.50$12,375.003,230,779View SEC Filing Icon  
6/23/2023Marlio Charles MosseriMajor ShareholderBuy73,175$17.43$1,275,440.252,511,265View SEC Filing Icon  
6/21/2023Marlio Charles MosseriMajor ShareholderBuy6,091$17.71$107,871.612,431,091View SEC Filing Icon  
6/21/2023Ron BentsurCEOBuy500$17.88$8,940.003,230,029View SEC Filing Icon  
6/15/2023Marlio Charles MosseriMajor ShareholderBuy32,124$17.71$568,916.042,412,300View SEC Filing Icon  
6/7/2023Ron BentsurCEOBuy230$17.41$4,004.303,229,409View SEC Filing Icon  
5/31/2023Ron BentsurCEOBuy330$17.28$5,702.403,229,179View SEC Filing Icon  
5/24/2023Ron BentsurCEOBuy200$17.49$3,498.003,228,849View SEC Filing Icon  
5/16/2023Ron BentsurCEOBuy320$17.02$5,446.403,228,649View SEC Filing Icon  
3/27/2023Enrique PoradosuInsiderBuy500$11.55$5,775.001,373,819View SEC Filing Icon  
3/23/2023Ron BentsurCEOBuy230$12.13$2,789.903,228,329View SEC Filing Icon  
3/21/2023Ron BentsurCEOBuy480$12.08$5,798.403,228,099View SEC Filing Icon  
3/21/2023Shay ShemeshInsiderBuy420$11.99$5,035.801,361,955View SEC Filing Icon  
3/15/2023Shay ShemeshInsiderBuy670$10.71$7,175.701,361,535View SEC Filing Icon  
3/14/2023Ron BentsurCEOBuy1,680$10.85$18,228.003,227,139View SEC Filing Icon  
12/21/2022Shay ShemeshInsiderBuy500$7.65$3,825.001,245,865View SEC Filing Icon  
11/30/2022Ron BentsurCEOBuy150$7.45$1,117.503,015,459View SEC Filing Icon  
11/28/2022Ron BentsurCEOBuy150$7.40$1,110.003,015,159View SEC Filing Icon  
11/25/2022Ron BentsurCEOBuy150$7.38$1,107.003,015,009View SEC Filing Icon  
11/17/2022Ron BentsurCEOBuy250$7.24$1,810.003,014,359View SEC Filing Icon  
11/16/2022Shay ShemeshInsiderBuy150$7.10$1,065.001,245,215View SEC Filing Icon  
11/10/2022Ron BentsurCEOBuy1,000$7.07$7,070.003,014,109View SEC Filing Icon  
9/30/2022Ron BentsurCEOBuy500$7.46$3,730.003,013,109View SEC Filing Icon  
9/28/2022Ron BentsurCEOBuy500$7.23$3,615.003,012,609View SEC Filing Icon  
9/26/2022Ron BentsurCEOBuy500$7.69$3,845.003,012,109View SEC Filing Icon  
9/23/2022Ron BentsurCEOBuy1,000$7.93$7,930.003,011,609View SEC Filing Icon  
9/23/2022Shay ShemeshInsiderBuy220$7.87$1,731.401,245,065View SEC Filing Icon  
8/29/2022Ron BentsurCEOBuy1,000$9.07$9,070.003,008,909View SEC Filing Icon  
8/23/2022Ron BentsurCEOBuy500$9.00$4,500.003,007,909View SEC Filing Icon  
8/18/2022Ron BentsurCEOBuy14,426$8.58$123,775.083,002,409View SEC Filing Icon  
8/11/2022Ron BentsurCEOBuy19,669$8.40$165,219.602,987,983View SEC Filing Icon  
6/28/2022Ron BentsurCEOBuy300$11.82$3,546.002,964,614View SEC Filing Icon  
6/24/2022Ron BentsurCEOBuy400$12.18$4,872.002,964,314View SEC Filing Icon  
6/22/2022Ron BentsurCEOBuy100$13.10$1,310.002,963,714View SEC Filing Icon  
5/26/2022Ron BentsurCEOBuy500$15.90$7,950.002,963,114View SEC Filing Icon  
5/20/2022Ron BentsurCEOBuy1,000$16.28$16,280.002,962,614View SEC Filing Icon  
5/20/2022Shay ShemeshInsiderBuy300$16.54$4,962.001,241,435View SEC Filing Icon  
5/18/2022Ron BentsurCEOBuy1,700$19.36$32,912.002,961,414View SEC Filing Icon  
5/16/2022Ron BentsurCEOBuy1,000$19.32$19,320.002,959,404View SEC Filing Icon  
5/16/2022Shay ShemeshInsiderBuy100$19.28$1,928.001,240,993View SEC Filing Icon  
5/12/2022Kenneth HobermanDirectorBuy6,000$17.40$104,400.0055,140View SEC Filing Icon  
5/12/2022Kenneth HobermanDirectorBuy6,000$17.40$104,400.0055,140View SEC Filing Icon  
5/12/2022Ron BentsurCEOBuy12,245$16.99$208,042.552,957,704View SEC Filing Icon  
5/12/2022Shay ShemeshInsiderBuy1,278$15.85$20,256.301,240,893View SEC Filing Icon  
3/28/2022Ron BentsurCEOBuy4,000$7.05$28,200.00View SEC Filing Icon  
3/17/2022Ron BentsurCEOBuy7,000$7.63$53,410.00View SEC Filing Icon  
2/14/2022Ron BentsurCEOBuy8,000$5.88$47,040.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Nuvectis Pharma (NASDAQ:NVCT)

96.77% of Nuvectis Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NVCT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Nuvectis Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
4/18/2024Blue Zone Wealth Advisors LLC14,350$0.12M0.0%N/A0.081%Search for SEC Filing on Google Icon
2/12/2024Edmond DE Rothschild Holding S.A.19,170$0.16M0.0%N/A0.111%Search for SEC Filing on Google Icon
1/30/2024Strs Ohio6,200$51K0.0%+59.0%0.036%Search for SEC Filing on Google Icon
1/8/2024Baldwin Brothers LLC MA142,040$1.19M0.1%+22.0%0.820%Search for SEC Filing on Google Icon
11/2/2023Forbes J M & Co. LLP34,000$0.44M0.1%-49.3%0.197%Search for SEC Filing on Google Icon
10/26/2023Strs Ohio3,900$50K0.0%+178.6%0.023%Search for SEC Filing on Google Icon
10/10/2023Baldwin Brothers LLC MA116,380$1.50M0.1%+29.2%0.675%Search for SEC Filing on Google Icon
8/10/2023Hollencrest Capital Management3,040$49K0.0%N/A0.019%Search for SEC Filing on Google Icon
8/4/2023American International Group Inc.3,298$53K0.0%N/A0.021%Search for SEC Filing on Google Icon
8/3/2023Forbes J M & Co. LLP67,000$1.07M0.1%N/A0.418%Search for SEC Filing on Google Icon
8/2/2023Bank of Montreal Can11,012$0.20M0.0%N/A0.069%Search for SEC Filing on Google Icon
7/14/2023Baldwin Brothers LLC MA90,061$1.44M0.1%-37.4%0.563%Search for SEC Filing on Google Icon
5/11/2023Edmond DE Rothschild Holding S.A.24,570$0.32M0.0%N/A0.167%Search for SEC Filing on Google Icon
4/21/2023Baldwin Brothers LLC MA143,800$1.89M0.2%+7.9%0.975%Search for SEC Filing on Google Icon
11/4/2022Ronit Capital LLP562,547$3.99M5.4%+34.2%3.843%Search for SEC Filing on Google Icon
10/14/2022Baldwin Brothers LLC MA133,000$0.94M0.1%+9.9%0.908%Search for SEC Filing on Google Icon
8/4/2022Ronit Capital LLP419,282$4.70M6.7%-23.8%3.297%Search for SEC Filing on Google Icon
7/18/2022Baldwin Brothers LLC MA121,000$1.36M0.2%N/A0.951%Search for SEC Filing on Google Icon
5/11/2022Ronit Capital LLP550,000$4.08M5.1%N/A4.325%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More on Nuvectis Pharma

Today's Range

Now: $7.10
Low: $6.81
High: $7.25

50 Day Range

MA: $8.46
Low: $6.41
High: $11.00

52 Week Range

Now: $7.10
Low: $6.20
High: $18.65

Volume

24,872 shs

Average Volume

98,648 shs

Market Capitalization

$126.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Who are the company insiders with the largest holdings of Nuvectis Pharma?

Nuvectis Pharma's top insider investors include:
  1. Ron Bentsur (CEO)
  2. Marlio Charles Mosseri (Major Shareholder)
  3. Enrique Poradosu (Insider)
  4. Shay Shemesh (Insider)
  5. Kenneth Hoberman (Director)
Learn More about top insider investors at Nuvectis Pharma.

Who are the major institutional investors of Nuvectis Pharma?

Nuvectis Pharma's top institutional shareholders include:
  1. Blue Zone Wealth Advisors LLC — 0.08%
Learn More about top institutional investors of Nuvectis Pharma stock.

Which major investors are buying Nuvectis Pharma stock?

In the previous quarter, NVCT stock was acquired by institutional investors including:
  1. Blue Zone Wealth Advisors LLC
In the previous year, these company insiders have bought Nuvectis Pharma stock:
  1. Ron Bentsur (CEO)
  2. Marlio Charles Mosseri (Major Shareholder)
  3. Enrique Poradosu (Insider)
  4. Shay Shemesh (Insider)
  5. Kenneth Hoberman (Director)
Learn More investors buying Nuvectis Pharma stock.